IP Library Granted Patent US 9,649,476
Granted Patent B2
US 9,649,476 · App. 13/866,547 · Granted May 16, 2017

Medical device for dispersing medicaments

Inventors: Ulrich Speck (Berlin, DE); Bruno Scheller (Saarbrucken, DE)
Assignee: Bayer Intellectual Property GmbH
A61M25/1002A61L29/08A61L29/085A61L29/16A61L31/08A61L31/16A61M25/0045A61M25/10A61M25/1027A61L2300/41A61L2300/412A61L2300/416A61L2300/43A61M25/104A61M25/1038A61M2025/0057A61M2025/1004A61M2025/105A61M2025/1031A61M2025/1075A61M2025/1086
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,649,476
App. No.
13/866,547
Granted
May 16, 2017
Kind
B2
Abstract

For selective treatment of diseased tissue sections or organ parts, the surface of medical devices entering into contact with areas thereof under pressure is coated with lipophilic substantially water-insoluble medicaments binding to various tissue components with good adherence thereto, said medicaments having an effect thereupon a short time after entering into contact therewith without exerting a harmful influence upon adjacent healthy tissue.

Claims (28)

1. A method of treating a vascular disease or circulation disturbance comprising: administering a device to affected tissue of a patient, wherein said device is a balloon catheter medical device comprising:

a balloon surface having paclitaxel embedded in a low-molecular weight matrix substance adhered thereto and dried,

wherein the dried paclitaxel is immediately releasable after coming into contact with tissue.

2. The method according to claim 1 , wherein said low-molecular weight matrix substance has a molecular weight of less than 5000 D and is selected from contrast agents and dyes used in vivo, sugars, sugar alcohols, low-molecular polyethylene glycols, and biocompatible organic and inorganic salts.

3. The method according to claim 1 , wherein said low-molecular weight matrix substance is selected from iodinated X-ray contrast agents, paramagnetic chelates, indocyanine green, fluorescein, and methylene blue.

4. The method according to claim 1 , wherein said low-molecular weight matrix substance is a readily water-soluble hydrophilic matrix substance.

5. The method according to claim 1 , wherein the low-molecular weight matrix substance has a molecular weight of less than 5000 D.

6. The method according to claim 1 , wherein the low-molecular weight matrix substance has a molecular weight of less than 2000 D.

7. The method according to claim 1 , wherein said balloon catheter medical device further comprises a stent.

8. The method according to claim 1 , wherein the balloon catheter medical device does not comprise a stent.

9. The method according to claim 1 , wherein the balloon surface has preformed longitudinal folds maintaining an inclination to refold after inflation.

10. The method according to claim 9 , wherein at least an area covered by the folds is covered with the paclitaxel.

11. The method according to claim 9 , wherein only an area covered by the folds is covered with the paclitaxel.

12. The method according to claim 1 , wherein the balloon surface consists of a very smooth material to which the paclitaxel embedded in the low-molecular weight matrix substance adheres sufficiently well to resist forces required for folding, essentially without damage.

13. The method according to claim 1 , wherein the balloon surface is coated by immersion in a low-viscosity paclitaxel solution while in a fully folded condition.

14. The method according to claim 1 , wherein the paclitaxel is present as a dry solid on the balloon surface.

15. The method according to claim 14 , wherein an effective dose of the paclitaxel includes amorphous structures with particle sizes ranging from <0.1 micron to 5 microns that dissolve quickly due to their large surface area and despite the poor water-solubility of the paclitaxel.

16. The method according to claim 1 , wherein the low-molecular weight matrix substance is hydrophilic.

17. The method according to claim 1 , wherein the paclitaxel is applied to the balloon surface with said low-molecular weight matrix substance.

18. The method according to claim 1 , wherein the balloon surface further comprises a substance that influences the gliding quality of the device or that prevents blood coagulation.

19. A method of opening a passage in the body comprising:

administering a device to said body, wherein said device is a balloon catheter medical device comprising:

a balloon surface having paclitaxel embedded in a low-molecular weight matrix substance adhered thereto and dried,

wherein the dried paclitaxel is immediately releasable after coming into contact with tissue.

20. A method for tumor treatment comprising:

administering a device to a patient, wherein said device is a balloon catheter medical device comprising:

a balloon surface having paclitaxel embedded in a low-molecular weight matrix substance adhered thereto and dried,

wherein the dried paclitaxel is immediately releasable after coming into contact with tissue.

Assignments (4)
CHANGE OF NAME Recorded Aug 6, 2014
From: BAYER PHARMA AKTIENGESELLSCHAFT
To: BAYER INTELLECTUAL PROPERTY GMBH
Reel/Frame 033476/0554 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2014
From: SCHELLER, BRUNO
To: SPECK, ULRICH
Reel/Frame 033481/0417 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2014
From: SPECK, ULRICH
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 033481/0969 →
CHANGE OF NAME Recorded Aug 6, 2014
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 033481/0972 →
Priority Claims (1)
DE 102 44 847 · Sep 20, 2002 · national
Continuity (3)
Division 12782989 · May 19, 2010
Division 10528577
Related Publication 20130231638A1 · Sep 5, 2013